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Abstract
 Purpose—Medication self-efficacy, or patients’ confidence that they can perform medication-
related behaviors, is associated with better glaucoma medication adherence. Little is known about 
how to enhance glaucoma patients’ medication self-efficacy. Our purpose is to examine whether 
patient-provider communication increases glaucoma patients’ medication self-efficacy.
 Methods—During an 8-month cohort study of 279 glaucoma patients and 15 providers, two 
office visits were videotape-recorded, transcribed, and coded for six patient-provider 
communication behaviors. A validated scale was used at baseline and 8-month follow-up to assess 
patients’ confidence in overcoming adherence barriers (adherence barriers self-efficacy) and 
carrying out tasks to use eye drops correctly (eye drop task self-efficacy). We ran two generalized 
estimating equations to examine whether more frequent patient-provider communication during 
office visits predicted increased patient adherence barriers self-efficacy and eye drop task self-
efficacy at 8-month follow-up.
 Results—For each additional topic providers educated about, patients reported an average 
increase of 0.35 in self-efficacy in overcoming adherence barriers (p<0.001). Patients also reported 
an average increase of 1.01 points in eye drop task self-efficacy when providers asked about 
patients’ views of glaucoma and its treatment versus not (p<0.001). Patients who asked more 
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medication questions (p<0.001) and African American patients (p<0.05) reported lower adherence 
barriers self-efficacy by 0.30 and 2.15 points, respectively. Women had a 0.63 lower eye drop task 
self-efficacy than men (p<0.05).
 Conclusions—When providers educate glaucoma patients and assess patient views about 
glaucoma and its treatment, patients report higher medication self-efficacy. Providers should be 
aware that patients who ask more medication questions may have less confidence in their ability to 
overcome barriers to adherence.
Keywords
glaucoma; self-efficacy; patient-provider communication; medication adherence; eye drop 
technique
Glaucoma is the leading cause of irreversible blindness worldwide, affecting approximately 
60 million people.1–3 Although glaucoma medications can slow disease progression and 
prevent blindness by lowering intraocular pressure, patients are unlikely to experience the 
clinical benefits of their glaucoma medications if they do not adhere to their medication 
regimen.4–6 Because glaucoma medication non-adherence rates range from 40–72%,4, 5, 7, 8 
researchers have attempted to identify and classify factors that promote and discourage 
patient adherence.9 Although numerous factors affect adherence, self-efficacy is a patient-
level factor that has consistently predicted patient adherence in chronic diseases 
generally10–12 and glaucoma specifically.13–15
Self-efficacy is defined as a person’s confidence to carry out a specific task in order to 
achieve a desired outcome.16, 17 Because glaucoma medications are administered via devices 
(i.e. eye drop bottles), patients may possess two types of medication self-efficacy: 
confidence to adhere to their regimens and confidence to administer their eye drops 
correctly.14 For glaucoma patients, higher adherence barriers self-efficacy has been 
associated with better self-reported medication adherence14, 15 as well as better medication 
adherence over a 60-day period as measured by electronic caps.13
Qualitative and quantitative studies have documented that patient-provider communication, 
including provider education and patient question-asking, are associated with better 
medication adherence for glaucoma patients.13, 18, 19 Although these previous studies have 
found direct links between communication and patient adherence, theoretical models posit 
that patient-provider communication most likely affects adherence indirectly through 
patient-mediated variables like increased self-efficacy.20–22 Indeed, in a study of HIV 
patients, adherence self-efficacy mediated the relationship between positive provider 
interactions and patient medication adherence.23 To our knowledge, no studies have 
examined whether patient-provider communication increases medication self-efficacy for 
glaucoma patients.
Our purpose is to address this research gap by examining whether patient-provider 
communication increases two types of medication self-efficacy for glaucoma patients. Using 
transcripts from two separate audiotaped office visits, we investigate whether six patient-
provider communication variables are associated with glaucoma patients’: 1) self-efficacy to 
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overcome adherence barriers and 2) self-efficacy to carry out specific tasks for using eye 
drop medications correctly. We hypothesize that patients will report higher self-efficacy 
levels when there is more frequent patient-provider communication during the office visits.
 MATERIALS AND METHODS
 Procedures
Data for this multisite cohort study were collected from six ophthalmology practices (2 
private offices and 4 academic ophthalmology departments) between 2009 and 2012. Four of 
the six practices were located in the southeastern United States, and the remaining two were 
located in the mid-Atlantic and West. Providers were told that the goal of the study was to 
learn about communication during glaucoma visits. Of the 16 providers invited to participate 
in the study, 15 agreed to participate.
Providers completed a demographic questionnaire and clinic staff referred potentially 
eligible patients to a research assistant, who explained the study to patients and administered 
an eligibility screener. Eligible patients: 1) were ≥18 years of age; 2) spoke English; 3) were 
glaucoma or glaucoma suspect patients; and 4) were mentally competent as determined by 
the Mental Status Questionnaire.24 Ineligible patients were given $5 to thank them for their 
time. Eligible patients provided informed consent, were enrolled, and had their office visit 
videotape-recorded. Videotapes were kept and the patient was followed for the 8-month 
study period if the patient was either: (a) newly-diagnosed with glaucoma and received a 
new prescription for glaucoma medications or (b) was already taking glaucoma medications.
There were three study visits: baseline, 4–6-week follow-up, and 8-month follow-up. 
Participants had their medical visits videotape-recorded at the baseline and 4–6-week visits. 
Immediately after their baseline and 8-month medical visits, a research assistant interviewed 
patients in a private examination room to assess their medication self-efficacy. Patients 
received $20 at each of the three visits to increase participant retention over the 8-month 
study period. This study received Institutional Review Board (IRB) approval and adhered to 
the tenets of the Declaration of Helsinki.
 Measures
The medical visit videotapes were de-identified and transcribed verbatim. The transcripts 
were reviewed by a research assistant who met twice a month with the investigators to 
develop a study codebook that contained the coding categories and rules. The coding rules 
and coding transcript sheets can be obtained by contacting the study principal investigator 
(Dr. Name Blinded). Three independent coders then used this codebook to code the 
transcripts for the patient-provider communication behaviors described below.
Over the course of the study, the three coders coded 25 of the same transcripts, which were 
selected at random, and met monthly to discuss discrepancies. Inter-rater correlations were 
used to assess inter-coder reliability. Inter-rater reliability for the variables ranged from 0.75 
to 1.0. If the communication behavior occurred very rarely, that limited our ability to 
calculate inter-rater reliability. In those cases, we calculated percent agreement between the 
coders; percent agreement was 0.72 to 1.00 for these variables.
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 Patient-Provider Communication Variables
 Patient question-asking about glaucoma medications—Patients’ medication-
related questions, included questions about medication regimen, installation procedures, side 
effects, purpose, adherence strategies, and other questions, were identified from each office 
visit transcript and recorded. A question-asking summary score was then created by adding 
together the total number of medication questions the patient asked at the baseline and 4–6-
week follow-up visit. If the patient asked the same question at both time points, this was 
recorded as two separate questions.
 Provider communication behaviors—For each visit, the coders documented 
whether the provider educated about the following glaucoma topics: (a) physical changes 
related to glaucoma; (b) emotional changes related to glaucoma; (c) diagnosis; (d) family 
history; (e) goals of treatment; (f) how to problem-solve glaucoma-related issues (not 
including managing physical or emotional changes); (g) intraocular pressure; (h) likelihood 
of long-term therapy; (i) glaucoma management plan; and (j) prognosis. Provider statements 
were coded into only one category; thus, coding categories were mutually-exclusive. 
Definitions of the 10 provider education categories listed above are included in the appendix. 
A provider education summary score was then created by adding together the total number 
of areas for which the provider educated the patient across the baseline and 4–6-week 
follow-up visit. If the provider educated about the same topic area at both office visits, this 
was recorded as two separate instances of education.
For each visit, the coders also recorded whether the provider: 1) asked the patient about their 
views of glaucoma and/or its treatment; 2) asked about patient confidence in using eye 
drops; 3) assessed if the patient had any questions; and 4) asked the patient to demonstrate 
their eye drop technique. Results were then summarized across both visits and each of the 
four provider communication behaviors listed above were coded as: 0= provider did this at 
neither visit, 1= provider did this at one visit, and 2= provider did this at both visits.
 Glaucoma medication self-efficacy—Immediately after the baseline and 8-month 
follow-up medical visit, patients completed a 35-item, validated, glaucoma medication self-
efficacy questionnaire.14 The questionnaire strongly correlates with self-reported and 
electronic measures of medication adherence.13, 14 The questionnaire possesses two 
subscales. The first subscale included 21 items that assess confidence in overcoming 
adherence-related barriers (i.e. adherence barriers self-efficacy), such as being able to take 
medications when travelling or when they cost a lot of money. The second subscale was 
comprised of 14 items that assess confidence in carrying out specific tasks to use eye drops 
correctly (eye drop task self-efficacy), including squeezing the bottle, getting the right 
number of drops into the eye, and not touching the eye with the bottle. Response options 
ranged from 1= ‘not at all confident’ to 3= ‘very confident.’ Items were summed for each 
scale and ranged from 21 to 63 for adherence barriers self-efficacy (Cronbach α=0.93) and 
14 to 42 for eye drop task self-efficacy (Cronbach α=0.84). Higher scores indicated greater 
self-efficacy.
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 Health literacy—Immediately before patients’ baseline office visit, the Rapid Estimate 
of Adult Literacy in Medicine (REALM) was administered to assess health literacy.25 The 
REALM is a validated, rapid screening instrument that identifies patients who have 
difficulty reading common medical terms.25, 26 REALM scores were then dichotomized to 
represent reading levels at or below eighth grade (0–60) or at or above ninth grade and above 
(61–66).
 Demographic and clinical characteristics—On the baseline questionnaire, patients 
reported their age (in years), gender, and race. Race was measured as a categorical variable 
(White, African American, Asian, Native American, and Hispanic) and then dichotomized to 
African American and non-African American. Prior use of glaucoma medications was 
assessed using a categorical variable that ranged from 1= ‘less than 6 months’ to 5= ‘5 years 
or more.’ Patients also indicated the number of glaucoma medications they were using. The 
severity of glaucoma for the worse eye was extracted from the patient’s medical chart at 
baseline and classified using the mean deviation of the eye, in decibels (dB), from the last 
reliable visual field and recoded as mild (≥6 dB), moderate (between −12 dB and −6 dB), 
and severe (≤ −12 dB) according to the Hodapp-Parrish-Anderson criteria.27
On the provider questionnaire, providers reported their age, gender, and race. Provider race 
was measured as a categorical variable (White, African American, Asian, Native American, 
and Hispanic). They also indicated whether they were a glaucoma specialist or not and the 
number of years since they had graduated from medical school.
 Data Analysis
We used SAS Version 9.3 (Cary, NC) to perform all analyses. We used descriptive statistics 
to characterize the sample and then ran chi-square tests and t-tests, as appropriate, to 
compare patients who completed the study with those who were lost to follow-up. We then 
ran two generalized estimating equations (GEEs) to determine whether patient-provider 
communication at the baseline and 4–6-week follow-up visits predicted increased adherence 
barriers self-efficacy and eye drop task self-efficacy at the 8-month follow-up visit (α=0.05). 
The GEE method is an extension of the generalized linear model. It accounts for the intra-
provider correlation of data from the multiple subjects enrolled for each provider to provide 
consistent estimates of model parameters.28 Six patient-provider communication variables, 
including the number of glaucoma medication topics the provider educated about, the 
number of glaucoma medication questions the patient asked, whether the provider asked 
about patient views of glaucoma and its treatment, whether the provider asked about patient 
confidence in using eye drops, whether the provider assessed if the patient had questions, 
and whether the provider asked the patient to demonstrate eye drop technique, were included 
as independent variables in each of the two GEE models. Each GEE model was clustered by 
provider and controlled for the following: provider age and gender; patient age, gender, race 
(African American vs not), and years of education; whether the patient was new to glaucoma 
medications; the number of glaucoma medications the patient was using; patient health 
literacy level; patient glaucoma severity in the worse eye; and patient baseline self-efficacy. 
Provider race was not included as a control variable because we only had one non-White 
physician.
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 RESULTS
 Sample Characteristics
Eighty-six percent (n=279) of eligible patients participated in the study and completed the 
baseline visit (Table 1). Eight-month adherence barriers self-efficacy and eye drop task self-
efficacy values were missing for 22 and 28 patients, respectively. Missing data were 
primarily due to losing 21 patients to follow-up. There were no demographic or clinical 
differences between those with and without an 8-month adherence barriers self-efficacy 
score. Those without 8-month eye drop task self-efficacy scores were less likely to have their 
provider assess whether they had questions (Pearson χ2= −9.87, df=3, p<0.01) and had 
providers who educated about fewer glaucoma topics (t(277) = −2.01, p<0.05) than those 
who had 8-month eye drop task self-efficacy scores.
Ten of the fifteen (67%) providers were male. Fourteen providers were White and one was 
African American. Provider age ranged from 26 to 66 years (mean 40.8 years, SD= 11.7 
years). Eighty percent (12) of providers were glaucoma specialists. The average years since 
graduation from medical school was 12.2 years (SD=11.4 years, range=1–38 years).
 Patient-provider Communication
Across both office visits, on average, providers educated about 3 glaucoma topics (SD=2.3, 
range=0–10) and patients asked 2.5 medication-related questions (SD=3.0, range=0–17). 
Providers rarely assessed patient views about glaucoma and its treatment or asked patients to 
demonstrate their eye drop technique; these communication behaviors occurred in fewer 
than 10% of visits. Providers asked about patient confidence in using eye drops more 
frequently; this occurred 24% (n=68) of the time at one visit and 7% (n=18) of the time at 
both visits. Providers assessed whether the patient had questions even more frequently; 33% 
(n=92) at one visit and 25% (n=71) at both visits.
 Generalized Estimating Equation Results
Table 2 presents the GEE results examining the relationships between patient-provider 
communication over the two tape-recorded visits and self-efficacy at the 8-month follow-up 
visit. When providers educated patients about more glaucoma topics, patients reported a 
significant increase in their confidence to overcome adherence-related barriers (β=0.35, 
p<0.001). For every topic that providers educated about, patients saw a 0.35 increase, on 
average, in their adherence-related barriers self-efficacy score. In contrast, patients who 
asked more questions about their glaucoma medications reported less adherence barriers 
self-efficacy than patients who asked fewer medication questions (β=−0.30, p<0.001). 
African Americans reported lower adherence barriers self-efficacy than non-African 
Americans (β=−2.15, p<0.05), meaning that African American patients scored 2.15 points 
lower, on average, on the adherence barriers self-efficacy scale than non-African American 
patients.
When providers asked patients about their views of glaucoma and its treatment, patients 
reported a significant increase of almost 1 point on average, in their eye drop task self-
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efficacy (β=1.01, p<0.0001). Women reported less eye drop task self-efficacy when 
compared with men (β=−0.63, p<0.05).
 DISCUSSION
This is the first study to examine whether patient-provider communication increases the 
medication self-efficacy of glaucoma patients. Our hypothesis that more frequent patient-
provider communication would be associated with higher levels of patient self-efficacy was 
partially supported; two of five provider communication behaviors predicted a significant 
increase in patient self-efficacy. Contrary to our hypothesis, we found that patients who 
asked more medication-related questions reported a decrease in self-efficacy at 8-month 
follow-up. None of the communication behaviors were significantly associated with both 
types of self-efficacy (adherence barriers and eye drop task), suggesting that the relationship 
between patient-provider communication and patient self-efficacy is complex and warrants 
further study.
Two provider communication behaviors, educating about glaucoma and asking about patient 
views of glaucoma and its treatment, were significantly associated with an increase in 
patient-reported self-efficacy. Although education alone is unlikely to improve patient 
adherence,29 our results suggest that education may help patients feel more confident they 
can overcome adherence barriers, which has been associated with better adherence to 
glaucoma medications in previous studies.13, 14 It is also possible that providers who spend 
more time educating their patients may be considered more patient-centered. A previous 
study with Danish cancer patients found that patients who reported that their provider was 
more attentive also reported greater self-efficacy to manage their disease.30 Similarly, HIV 
patients who reported more frequent positive interactions with their physicians had greater 
adherence self-efficacy.23 Thus, taking the time to educate patients about glaucoma and 
assess their views may be effective methods for increasing medication self-efficacy, and 
interventions designed to increase patient medication-related self-efficacy should consider 
including components to help providers communicate with patients in a more patient-
centered manner.
Future studies should explore whether self-efficacy mediates the relationship between 
provider communication and patient adherence to glaucoma medications. Although previous 
research has found direct links between patient-provider communication and medication 
adherence,13, 31 it is likely that this relationship may be mediated by self-efficacy.20, 21 
Indeed, one study with HIV patients found that the relationship between communication and 
adherence is almost completely mediated through increased self-efficacy.23 Because we 
found that women and African Americans reported lower medication self-efficacy, future 
studies should also examine whether the effects of communication on self-efficacy vary by 
patient race and gender.
Neither asking about patient confidence in using eye drops (p=0.40) nor asking patients to 
demonstrate their eye drop technique (p=0.54) were associated with patient eye drop task 
self-efficacy. Without information about whether and how often patients received eye drop 
technique instruction and whether patients received quality technique instruction prior to the 
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visits that were tape-recorded as part of this study, it is difficult to make definite conclusions 
about how technique education is related to patient technique. Patient eye drop task self-
efficacy scores were very high at baseline and follow-up, and previous analyses from this 
study have shown that despite these high self-efficacy scores, most patients demonstrate 
suboptimal eye drop technique.32 A similar issue regarding patient overconfidence in 
medication administration abilities has been reported in the pediatric asthma literature.33 
Thus, patients may be overconfident in their ability to use their eye drops correctly, limiting 
our ability to show relationships between communication and increased self-efficacy. Even 
though asking about patient views of glaucoma and its treatment only occurred in fewer than 
10% of visits, this provider communication behavior was significantly related to increased 
eye drop task self-efficacy. Future studies should explore why asking about patient views 
would improve eye drop task self-efficacy more than asking about confidence in using eye 
drops or asking patient to demonstrate their eye drop technique.
We were surprised that patients who asked more medication-related questions during their 
office visits reported lower confidence to overcome adherence-related barriers. Previous 
qualitative research with glaucoma patients found that non-adherent patients were less likely 
to ask their provider questions.19 Thus, we assumed that question-asking would result in 
patients receiving more information about their medications, which could increase their 
confidence to use their medications as prescribed.34 One possible explanation for this 
finding could be that asking questions did not result in the patients being able to overcome 
particular adherence-related barriers; hence, their confidence levels remained low. For 
example, if a patient had difficulty paying for their glaucoma medications and asked the 
provider a cost-related question, simply answering the patient’s question may not have 
helped the patient pay for the medication. Thus, their adherence barriers self-efficacy could 
have remained low even though they asked a question.
Providers should be aware that patients who ask more medication-related questions may 
have less confidence they can adhere to their glaucoma medications. Previous analyses from 
this study have shown that patients who are new to medications are more likely to ask 
providers questions than patients who have been taking medications.35 This could be 
because new patients have not had time to establish confidence in their medication-taking 
routine. Future studies should conduct more in-depth analyses to explore how being newly-
diagnosed with glaucoma may interact with other variables to affect patient-provider 
communication and clinical outcomes. Asking patients, especially new patients, about their 
barriers to adherence and referring them to other office personnel (e.g. technicians, nurse 
educators) who can spend more time answering patient questions and potentially refer them 
to additional community resources, such as non-profit organizations, may help patients 
address their barriers, which could potentially improve their self-efficacy and ultimately 
their medication adherence.
 Limitations
This study has several limitations and results should be interpreted with caution. First, study 
staff did not track the characteristics of patients who declined to speak with the research 
assistant, so we could not calculate a patient participation rate or estimate the effects of 
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selection bias. Second, providers and patients both knew the visit was being recorded, but 
they did not know the study hypotheses. Even if there was a Hawthorne effect,36 it was 
likely small, as patient-provider communication behaviors occurred infrequently. Third, due 
to the relative infrequency with which various types of provider communication occurred, 
the study coders counted the patient being educated about glaucoma or glaucoma 
medications during visits regardless of whether the provider was a physician or technician. 
Thus, we cannot separate out variance in communication effects due to provider type (e.g. 
physician, technician). Fourth, we quantified communication behaviors in order to include 
them in regression models. Accounting for the quality of communication could have 
explained additional variance in medication-taking behaviors and clinical outcomes. Thus, 
future studies should examine both the quality and quantity of communication. Additionally, 
patients’ self-efficacy was measured immediately after their baseline and 8-month follow-up 
visits. Thus, it is possible that patients’ self-efficacy levels could have been immediately 
influenced by communication that took place during the visit. Future studies should assess 
self-efficacy before and after visits to determine whether there are immediate effects of 
communication on self-efficacy. Also, most patients in this sample were not new to eye 
drops and may have received education about their glaucoma and glaucoma medications at a 
previous visit, which could account for the low frequency with which education was 
provided in the current study.
Our results indicate that educating patients about their glaucoma and assessing their views 
about glaucoma and its treatment can improve patients’ medication self-efficacy. Thus, 
providers should engage in these communication behaviors during visits with their glaucoma 
patients, since increasing self-efficacy can improve medication adherence.13–15 Providers 
should also be aware that patients who ask more medication-related questions may have less 
confidence that they can overcome adherence-related barriers and make sure these patients 
are referred to resources that can help them address these barriers.
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Table 1
Patient Characteristics (N=279).
Characteristic %(N)
Male 41 (114)
Race
 African American 36 (99)
 Non-African American 64 (179)
Age (in years)
 Mean (SD), range 65.8 (12.8), 21–93
Years of education
 Mean (SD), range 15.1 (3.5), 5–26
Health literacy; reading level ≤8th grade 84 (233)
Newly prescribed glaucoma medications 18 (51)
Prior use of glaucoma medications
 Less than 6 months 17 (47)
 6 months to less than 1 year 10 (29)
 1 year to 2 years 10 (29)
 More than 2 years to less than 5 years 16 (45)
 5 years or more 28 (78)
Number of glaucoma medications patient is taking*
 One 62 (173)
 Two 28 (79)
 Three 5 (13)
 Four 1 (2)
Glaucoma severity (worse eye)
 Mild 62 (162)
 Moderate 21 (55)
 Severe 17 (45)
Adherence barriers self-efficacy at baseline Mean (SD), rang 58.9 (5.5), 28–63
Adherence barriers self-efficacy at 8-month follow-up Mean (SD), range 59.0 (5.8), 25–63
Eye drop task self-efficacy at baseline Mean (SD), range 39.8 (2.6), 29–42
Eye drop task self-efficacy at 8-month follow-up Mean (SD), range 39.8 (3.0), 25–42
*
Total does not add to 100% due to missing values
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